Biotechnology
PHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer Screening
GUANG'AN, China, Sept. 22, 2025 /PRNewswire/ -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an,Sichuan Province, Chin...
2025-09-22 15:39
2505
First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...
2025-09-22 12:29
4131
Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...
2025-09-19 20:00
3198
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...
2025-09-19 19:59
5819
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries SINGAPORE, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0. Since its...
2025-09-19 16:58
2176
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries CANBERRA, Australia, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....
2025-09-19 16:51
2337
Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes
Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries MANILA, Philippines, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....
2025-09-19 16:04
2428
Beyond Ventures Champions HKIC's new initiatives outlined in The Policy Address 2025
Strategic partnership with the HKIC fuels growth across biotech, hardcore and greentech sectors, reinforcingHong Kong's role as a super-connector and super value-adder in the global innovation landscape HONG KONG, Sept. 18, 2025 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Venture...
2025-09-18 17:57
2727
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 18, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by Reme...
2025-09-18 09:00
2729
Terra Oleo Emerges from Stealth with US$3.1M in Funding and Breakthrough Energy Fellow Selection to Reinvent Fats and Oils
SINGAPORE, Sept. 18, 2025 /PRNewswire/ -- Terra Oleo, a Singapore-based biotechnology company, today announced its emergence from stealth withUS$3.1 million in funding from a group of investors, and support from Breakthrough Energy's prestigious Fellows Program. As part of this highly selective g...
2025-09-18 00:00
4426
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile SKY-0515's Phase 2/3 FALCON-HD t...
2025-09-17 20:44
1857
New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic and Muscle Health
Emerging evidence positions this dairy protein as a powerful nutritional ingredient – and 21st.BIO's precision fermentation could make it more sustainable than ever. COPENHAGEN, Denmark, Sept. 16, 2025 /PRNewswire/ -- β-Lactoglobulin (BLG), the most abundant whey protein in cow's milk is drawing...
2025-09-16 21:47
1996
ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its RELIEV-CM Pilot Study. The findings demonstrate sustaine...
2025-09-16 19:00
1795
Celebrating Cross-Border Partnerships in Healthcare, Asia Medical Week 2025 Convened Leaders in Bali to Strengthen Excellence and Preparedness
BALI, Indonesia, Sept. 16, 2025 /PRNewswire/ -- The Asia Medical Week (AMW) and the Asia Medical Innovation and Development Forum 2025 officially took place fromSeptember 12-13 in Bali with a mission to bring together healthcare leaders from acrossAsia to strengthen cross-border collaboration and...
2025-09-16 13:37
2261
Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of RN3161 to the Australian Human Research Ethics Committee (HREC).RN3161 is a proprietary GalNAc-conjug...
2025-09-15 20:00
2499
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc
Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 /PRNewswi...
2025-09-15 12:06
1836
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation 'Data Mining Machine' for Genomics
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for larg...
2025-09-15 11:53
2876
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initi...
2025-09-15 08:00
2469
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
* 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025). * The newly released results, based on clinical practices at several leading hospitals inChina, offer a comprehensive overview of the efficacy and safety of NEFE...
2025-09-15 07:45
5586
/C O R R E C T I O N -- Mars/
In the news release, Mars Snacking and Unreasonable Group Welcome Fourteen New Ventures to Unreasonable Food™, issued11-Sep-2025 by Mars over PR Newswire, we are advised by the company that the release has been updated to include the full 2025 Unreasonable Food cohort. The complete, corrected rel...
2025-09-13 06:14
6278
Week's Top Stories
Most Reposted
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
PHOTO & IMAGE SHANGHAI 2026 to Showcase AI Imaging, Content-Creation Technologies and Emerging Visual Trends This July
[Picked up by 269 media titles]
2026-05-29 17:36
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7952
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7425
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
6874
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6588